Cancer
Neoplasm of Uncertain Histogenesis
CI-CAN-00000034Explore in graph →
Non-malignant20,280 active trials259 approved drugs3,813 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00000034Explore in graph →
Clinical trials
91,351 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00186316 | Vaccine Therapy for Multiple Myeloma Utilizing Idiotype-Pulsed Allogeneic Dendritic Cells | completed | Phase 1 / Phase 2 | 30 | Stanford UniversityOTHER | 1 | Aug 25, 2009 | clinicaltrials |
| NCT00625768 | Study of AS1409 in Patients With Either Metastatic Renal Cell Carcinoma or Metastatic Malignant Melanoma | completed | Phase 1 | 13 | Antisoma ResearchINDUSTRY | 2 | Aug 25, 2009 | clinicaltrials |
| NCT00496704 |
| Gemcitabine, Capecitabine, and Oxaliplatin as Second-Line Therapy in Treating Patients With Advanced Colorectal Cancer Previously Treated With Irinotecan |
| unknown |
| Phase 1 / Phase 2 |
| 56 |
| Yonsei UniversityOTHER |
| 1 |
| Aug 21, 2009 |
| clinicaltrials |
| NCT00327249 | Safety and Efficacy Study of Imexon for Treatment of Multiple Myeloma Patients | completed | Phase 1 / Phase 2 | — | AmpliMed CorporationINDUSTRY | 1 | Aug 11, 2009 | clinicaltrials |
| NCT00307723 | Study of Bevacizumab in Combination With 5-FU, Oxaliplatin and External Beam Radiation Followed by Gemcitabine and Bevacizumab for Locally Advanced Pancreatic Cancer | terminated | Phase 1 / Phase 2 | 52 | Massachusetts General HospitalOTHER | 0 | Aug 10, 2009 | clinicaltrials |
| NCT00955292 | Dose-escalation Study of Quarfloxin in Patients With Advanced Solid Tumors or Lymphomas | terminated | Phase 1 | 12 | Cylene PharmaceuticalsINDUSTRY | 1 | Aug 10, 2009 | clinicaltrials |
| NCT00955786 | Dose-escalation Study of CX-3543 in Patients With Advanced Solid Tumors or Lymphomas | completed | Phase 1 | 48 | Cylene PharmaceuticalsINDUSTRY | 1 | Aug 10, 2009 | clinicaltrials |
| NCT00418327 | Safety Study of Tarceva in Children With Refractory and Relapsed Malignant Brain Tumors and Newly Diagnosed Brain Stem Glioma | completed | Phase 1 | 48 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Aug 7, 2009 | clinicaltrials |
| NCT00169000 | Safety Study of a New Schedule of Capecitabine and Docetaxel to Treat Cancers | completed | Phase 1 | 12 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | Aug 6, 2009 | clinicaltrials |
| NCT00306813 | Evaluation of Lenalidomide, Doxorubicin and Dexamethasone (RAD) in Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 53 | University of WuerzburgOTHER | 1 | Aug 4, 2009 | clinicaltrials |
| NCT00354900 | Phase I Study of Aprotinin in Advanced Breast Cancer | terminated | Phase 1 | 18 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | Aug 4, 2009 | clinicaltrials |
| NCT00558922 | A Phase 1-2 XIAP Antisense AEG35156 With Carboplatin and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 54 | Aegera TherapeuticsINDUSTRY | 1 | Jul 30, 2009 | clinicaltrials |
| NCT00944801 | Pegylated Liposomal Doxorubicine and Prolonged Temozolomide in Addition to Radiotherapy in Newly Diagnosed Glioblastoma | completed | Phase 1 / Phase 2 | 63 | University of RegensburgOTHER | 1 | Jul 23, 2009 | clinicaltrials |
| NCT00613652 | A Phase I, Dose-Escalation Study to Assess the Safety and Drug Levels in Blood of AZD4877 in Japanese Adult Patients | completed | Phase 1 | 30 | AstraZenecaINDUSTRY | 1 | Jul 21, 2009 | clinicaltrials |
| NCT00591058 | Safety and Dose-Finding Study of TM-601 in Adults With Recurrent Malignant Glioma | unknown | Phase 1 | 36 | TransMolecularINDUSTRY | 1 | Jul 17, 2009 | clinicaltrials |
| NCT00683761 | A Study of 131I-TM601 in Adults With Recurrent Malignant Glioma | unknown | Phase 1 / Phase 2 | 64 | TransMolecularINDUSTRY | 1 | Jul 17, 2009 | clinicaltrials |
| NCT00759837 | Study Evaluating The Pharmacokinetics (PK) And Safety Of Bosutinib In Subjects With Liver Disease And In Healthy Subjects | completed | Phase 1 | 27 | Wyeth is now a wholly owned subsidiary of PfizerINDUSTRY | 1 | Jul 16, 2009 | clinicaltrials |
| NCT00107861 | Interferon-Beta Gene Transfer (Ad.hIFN-β) as Treatment for Refractory Colorectal Carcinoma With Liver Metastases | completed | Phase 1 / Phase 2 | 44 | BiogenINDUSTRY | 1 | Jul 14, 2009 | clinicaltrials |
| NCT00345189 | Study of Oral CNF2024 (BIIB021) in Advanced Solid Tumors | completed | Phase 1 | 70 | BiogenINDUSTRY | 2 | Jul 14, 2009 | clinicaltrials |
| NCT00053105 | Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma | unknown | Phase 1 | — | TheradexINDUSTRY | 1 | Jul 7, 2009 | clinicaltrials |
| NCT00390195 | Randomized Phase I/II of RAD001 in Advanced Hepatocellular Carcinoma (HCC) | unknown | Phase 1 / Phase 2 | 134 | National Health Research Institutes, TaiwanOTHER | 1 | Jul 2, 2009 | clinicaltrials |
| NCT00181506 | HI-CHART:Feasibility of High-Dose Accelerated Conformal Radiotherapy | completed | Phase 1 / Phase 2 | 180 | Maastricht Radiation OncologyOTHER | 1 | Jun 30, 2009 | clinicaltrials |
| NCT00181545 | Safety Study of Individualised Radiation Dose Determination for Lung Cancer Patients. | completed | Phase 1 | 30 | Maastricht Radiation OncologyOTHER | 1 | Jun 30, 2009 | clinicaltrials |
| NCT00690053 | Non-Invasive Imaging of [18F]HX4 With Positron-Emission-Tomography (PET)(HX-4) | completed | Phase 1 | 12 | Maastricht Radiation OncologyOTHER | 1 | Jun 30, 2009 | clinicaltrials |
| NCT00675727 | Safety Study of CADI-05 in Patients With Advanced Stage Melanoma | terminated | Phase 1 / Phase 2 | 20 | Cadila PharnmaceuticalsINDUSTRY | 1 | Jun 11, 2009 | clinicaltrials |
| NCT00004086 | Radiolabeled Monoclonal Antibody, Combination Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory B-Cell Cancer | unknown | Phase 1 | — | Garden State Cancer Center at the Center for Molecular Medicine and ImmunologyOTHER | 1 | Jun 9, 2009 | clinicaltrials |
| NCT00344786 | Phase 1, Dose-Escalation Study of Oral CNF2024(BIIB021) in CLL | terminated | Phase 1 | 15 | BiogenINDUSTRY | 1 | Jun 5, 2009 | clinicaltrials |
| NCT00113724 | Study of TPI 287 in Patients With Advanced Malignancies | completed | Phase 1 | 48 | Cortice Biosciences, Inc.INDUSTRY | 1 | Jun 4, 2009 | clinicaltrials |
| NCT00032903 | This is an Early Study to Investigate the Effect of Gimatecan® in Adults With Malignant Glioma. | completed | Phase 1 / Phase 2 | 59 | Sigma-Tau Research, Inc.INDUSTRY | 1 | Jun 3, 2009 | clinicaltrials |
| NCT00288925 | Z-360 in Unresectable Advanced Pancreatic Cancer in Combination With Gemcitabine Treatment | completed | Phase 1 / Phase 2 | 30 | Zeria PharmaceuticalINDUSTRY | 1 | Jun 1, 2009 | clinicaltrials |
| NCT00352677 | Safety and Tolerability Study of INNO-406 to Treat Chronic Myeloid Leukemia or Acute Lymphocytic Leukemia | completed | Phase 1 | 100 | CytRxINDUSTRY | 3 | Jun 1, 2009 | clinicaltrials |
| NCT00664170 | A Bioequivalence Study of Docetaxel for Injectable Emulsion (ANX-514) in Patients With Advanced Cancer | completed | Phase 1 | 39 | Mast Therapeutics, Inc.INDUSTRY | 3 | May 28, 2009 | clinicaltrials |
| NCT00389285 | Study of Recombinant Interleukin 21 in Combination With Sorafenib for Metastatic Renal Cell Carcinoma | completed | Phase 1 / Phase 2 | 52 | ZymoGeneticsINDUSTRY | 1 | May 27, 2009 | clinicaltrials |
| NCT00904852 | Safety Study of the Combination of Tandutinib With Temozolomide and Bevacizumab After Radiation and Temozolomide in Patients With Newly Diagnosed With Glioblastoma Multiforme | withdrawn | Phase 1 | 30 | Millennium Pharmaceuticals, Inc.INDUSTRY | 0 | May 20, 2009 | clinicaltrials |
| NCT00854854 | Efficacy Study of TKcell in Advanced Gastric Cancer | unknown | Phase 1 / Phase 2 | 94 | BinexINDUSTRY | 1 | May 18, 2009 | clinicaltrials |
| NCT00854971 | Efficacy Study of TKcell in Advanced Colorectal Cancer | unknown | Phase 1 / Phase 2 | 86 | BinexINDUSTRY | 1 | May 18, 2009 | clinicaltrials |
| NCT00543972 | Dose Escalation Safety and Pharmacokinetic Study of AVE9633 as Single Agent in Relapsed/Refractory CD33-Positive Acute Myeloid Leukemia | terminated | Phase 1 | 12 | SanofiINDUSTRY | 3 | May 14, 2009 | clinicaltrials |
| NCT00119600 | A Study of AMG 114 Administered by Subcutaneous Injection for the Treatment of Anemia in Subjects With Non-Myeloid Malignancies Receiving Multicycle Chemotherapy | terminated | Phase 1 / Phase 2 | — | AmgenINDUSTRY | 0 | May 11, 2009 | clinicaltrials |
| NCT00733798 | A Safety and Efficacy Study of Intravenous 131I-TM601 in Adult Patients With Malignant Melanoma | terminated | Phase 1 / Phase 2 | 58 | TransMolecularINDUSTRY | 1 | May 11, 2009 | clinicaltrials |
| NCT00895466 | Efficacy and Safety Study of the Therapeutic Vaccine PEP223 in Prostate Cancer Patients | unknown | Phase 1 / Phase 2 | 12 | Pepscan TherapeuticsINDUSTRY | 1 | May 8, 2009 | clinicaltrials |
| NCT00683358 | Human Leukocyte Antigen-A*2402-Restricted Tumor Vessel Specific Peptide Vaccination for Advanced Pancreatic Cancer | unknown | Phase 1 / Phase 2 | 14 | Tokyo UniversityOTHER | 1 | May 7, 2009 | clinicaltrials |
| NCT00506402 | A Phase 1 Study of MKC-1 in Patients With Refractory Hematologic Malignancies | completed | Phase 1 | 30 | CASI pharmaceuticals, Inc.INDUSTRY | 1 | May 5, 2009 | clinicaltrials |
| NCT00096707 | Dose Escalation Trial of 2-Deoxy-D-Glucose (2DG) in Subjects With Advanced Solid Tumors | completed | Phase 1 | 50 | Threshold PharmaceuticalsINDUSTRY | 1 | Apr 29, 2009 | clinicaltrials |
| NCT00890110 | Autologous Vaccination of Stage 4 Renal Cell Carcinoma Combined With Sunitinib(rcc) | unknown | Phase 1 / Phase 2 | 13 | Hadassah Medical OrganizationOTHER | 0 | Apr 29, 2009 | clinicaltrials |
| NCT00075933 | ARQ 501 in Subjects With Cancer | completed | Phase 1 | 80 | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)INDUSTRY | 1 | Apr 28, 2009 | clinicaltrials |
| NCT00099190 | ARQ 501 in Combination With Docetaxel in Patients With Cancer | completed | Phase 1 | 50 | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)INDUSTRY | 1 | Apr 28, 2009 | clinicaltrials |
| NCT00234416 | IRESSA Combined With Radiotherapy & Gemcitabine as First-Line Treatment in Locally Advanced Pancreatic Cancer | completed | Phase 1 / Phase 2 | 45 | AstraZenecaINDUSTRY | 1 | Apr 23, 2009 | clinicaltrials |
| NCT00242788 | IRESSA™ In Combo With Xeloda™ in Advanced Colorectal Cancer Patients After 1st-Line Chemo Failure | completed | Phase 1 / Phase 2 | 40 | AstraZenecaINDUSTRY | 1 | Apr 23, 2009 | clinicaltrials |
| NCT00547404 | Phase I Study for Safety and Efficacy of P276-00 in Subjects With Myeloma | withdrawn | Phase 1 | 35 | Piramal Enterprises LimitedINDUSTRY | 0 | Apr 23, 2009 | clinicaltrials |
| NCT00106626 | Suberoylanilide Hydroxamic Acid in Advanced Solid Tumors | completed | Phase 1 | 52 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Apr 22, 2009 | clinicaltrials |
Data updated 23 days agoSource updated Aug 25, 2009source: clinicaltrials